Click here for slides on this topic


Hypoglycemia

Low blood glucose levels. Symptoms include adrenergic symptoms (tremor, sweating, palpitations - mediated by increased epinephrine) and neuroglycopenic (mood change, confusion, dizziness or disequilibrium, lethargy, compa - mediated by inadequate energy supply the brain) moodiness, numbness in the arms and hands, confusion and shakiness, or dizziness. If left untreated, hypoglycemia can cause sudden loss of consciousness.


The following content matched the glossary term: Hypoglycemia

AHA ADA prevention of CVD in T2D - Hypoglycemia & CVD

Top

Summary of evidence for hypoglycemia & cardiovascular disease (CVD) from the AHA ADA CVD prevention in type 2 diabetes guidelines.

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association

Top

Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts

AACE 2015 guidelines Hypoglycemia Management

Top

Summary of recommendations for managing hypoglycemia from the 2015 AACE diabetes treatment guidelines 

AACE 2015 guidelines Glycemic Targets

Top

Summary of glycemic treatment targets, including the A1C goal, from the 2015 AACE diabetes guidelines 

NDEI.org Expert Commentary Silvio E. Inzucchi MD on the Association Between Severe Hypoglycemia

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "This paper adds to a growing body of literature demonstrating the higher cardiovascular risk of patients with type 2 diabetes and a history of severe hypoglycemia"

NDEI.org Expert Commentary Phentermine-topiramate for weight loss in type 2 diabetes Silvio Inzucchi

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "Weight loss remains a great challenge for our patients, especially those with diabetes."

Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Bedenis R, Price AH, Robertson CM, et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2014. [ePub ahead of print] doi: 10.2337/dc14-0908.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin + MDI insulin

Top

Rosenstock J, Jelaska A, Frappin G, et al; on behalf of the EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014. DOI:10.2337/dc13-3055.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Hypoglycemia Slides Found: 161
Pramlintide Adjunctive Therapy Offers Long-Term Glycemic Control
Effect of Pramlintide Adjunctive Therapy on Weight in Patients With Type 2 Diabetes
Adverse Events Associated With Thiazolidinedione Treatment
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
18-Wk Sitagliptin Monotherapy Improves Glycemic Control
18-Wk Sitagliptin Monotherapy Improves b-Cell Function
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
ADOPT: Adverse Events
Vildagliptin + Pioglitazone Improves A1C in Patients Not Controlled With Thiazolidinedione Monotherapy
Change in A1C for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Vildagliptin: Change in Mean A1C During 24-Week Treatment
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on A1C in Patients With Type 2 Diabetes
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Hypoglycemia Risk Factors in Elderly Patients With Type 2 Diabetes
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
ADVANCE Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
Alogliptin Monotherapy: A1C
Alogliptin and Glyburide Combination Therapy: A1C
Alogliptin Added to Metformin: A1C
Alogliptin Added to Insulin: A1C
12-Week Saxagliptin Improves Glycemic Control in Drug-Naïve Patients
VADT: Comparing Intensive With Standard Glucose Therapy, Adverse Events
Type 2 Diabetes Therapy and Cardiovascular Events: Comparing VADT With Other Trials
Alogliptin Study 010: Safety
ACCORD: Annual Incidence of Hypoglycemia in the Intensive Versus Standard Treatment Groups
ACCORD: Hypoglycemia and Mortality
VADT: Effect of BMI on Rates of Severe Hypoglycemia
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results Design
DURATION-4: Most Common Adverse Events
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Results
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Conclusions
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
Vascular Risk Associated with Medication-Related Hypoglycemia: Design
Cumulative Incidence of CVD: Hypoglycemia Group vs Control
Cumulative Incidence of Microvascular Complications: Hypoglycemia Group vs Control
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Design
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
EUREXA Trial: Hypoglycemia and Adverse Events
BLOOM-DM: Adverse Events
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Secondary Endpoints
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Individualizing Treatment (2 of 2)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (2 of 3)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (3 of 3)
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: 26-Week Extension Results for A1C Reduction
Liraglutide Treatment for 78 Weeks: Reductions in A1C from Baseline
DURATION-6: Adverse Events
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (1 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (2 of 2)
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
Inpatient Glycemic Control: Is There an Optimal Insulin Strategy?
Basal Plus Trial: Design and Randomization
Basal Plus Trial: Hypoglycemia
ADA/Endocrine Society: Definition of Hypoglycemia in Diabetes
ADA/Endocrine Society: Classification of Hypoglycemia in Diabetes
ADA/Endocrine Society: Impact of Hypoglycemia on Glycemic Targets
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (1 of 2)
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (2 of 2)
ADA/Endocrine Society: Hypoglycemia & the Elderly
ADA/Endocrine Society: Minimizing Hypoglycemia Risks in the Elderly
ADA/Endocrine Society: Impact of Hypoglycemia on Hospitalized Patients
ADA/Endocrine Society: Hypoglycemia and Quality of Life
CANTATA-D2: Adverse Events at 52 Weeks
CANTATA-M: Adverse Events with Canagliflozin Vs Placebo at 26 Weeks
ACP Guidelines: Inpatient Hyperglycemia Management with IIT
ACP Guidelines: Inpatient Hyperglycemia Management with IIT
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
Meta-Analysis: Severe Hypoglycemia Associated with ~2x Risk for CVD
SAVOR-TIMI 53: Safety Endpoints
EXAMINE: Adverse Events
ADA Nutrition Guidelines: Protein
ADA Nutrition Guidelines: Alcohol
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, Change in A1C at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in Patients With Type 2 Diabetes
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Body Weight in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Fasting Plasma
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on A1
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Body
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Fasting
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
IDF 2012 Type 2 Diabetes Guidelines Dietary Guidelines | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Glycemic Control | NDEI
IDF Guidelines Type 2 Diabetes Diagnosis Older Adults Elderly | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
IDF Type 2 Diabetes Guidelines In-Patient Critically Ill | NDEI
Emplagliflozin SGLT 2 A1C EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Weight Loss EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Insulin EMPA-REG MDI Study | NDEI
Empagliflozin SGLT2 Adverse Events EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 EMPA-REG MDI Study | NDEI
Diabetes Pregnancy Guidelines Endocrine Society GDM A1C | NDEI
Diabetes Pregnancy Guidelines Endocrine Society Glucose Monitoring | NDEI
Diabetes Pregnancy Guidelines Insulin Therapy | NDEI
Diabetes Complications Hypoglycemia US Adults 2012 | NDEI
SGLT2 Inhibitors Type 2 Diabetes Treatment Slides | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
Edinburgh Type 2 Diabetes Study Severe Hypoglycemia Slide PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Macrovascular Slides PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Inflammation Slides PPT | NDEI
Edinburgh Type 2 Diabetes Inflammation Doesn't Influence Hypoglycemia Slides PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Macrovascular Death Slides PPT | NDEI
ADVANCE-ON Type 2 Diabetes Primary Outcomes Intensive Glucose Slide | NDEI
SGLT2 Dapagliflozin + Insulin Type 1 Diabetes Treatment Slide | NDEI
Adverse Events Dapagliflozin As Insulin Adjunct in Type 1 Diabetes | NDEI
Dapagliflozin Type 1 Diabetes SGLT2 Data Review | NDEI
ACCORD-MIND Hypoglycemia Brain Structure Type 2 Diabetes | NDEI
ACCORD-MIND Hypoglycemia Age, Intensive Therapy, Diabetes Duration | NDEI
ACCORD-MIND Hypoglycemia Doesn't Alter Brain Function Type 2 Diabetes | NDEI
ACCORD-MIND Summary Hypoglycemia Cognitive Function Type 2 Diabetes | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
Concomitant Autoimmunity
ADA Type 1 Diabetes Guidelines Children and Adolescent Treatment | NDEI
ADA Type 1 Diabetes Guidelines Nutrition Therapy | NDEI Slides
ADA Type 1 Diabetes Guidelines Physical Activity | NDEI Diabetes Slides
A1C Targets for Nonpregnant Individuals
Glycemic Goals for Adults With Type 1 Diabetes
Glucose Monitoring SMBG CGM ADA Type 1 Diabetes Guidelines | NDEI
Insulin Therapy ADA Type 1 Diabetes Guidelines | NDEI Slides
Beta-Cell Replacement ADA Type 1 Diabetes Guidelines | NDEI
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
A1C Targets Pregnancy ADA Type 1 Diabetes Guidelines | NDEI Slides
Inpatient Outpatient Management ADA Type 1 Diabetes Guidelines | NDEI
Child Care Recommendations ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Position Statement Insulin Use in Type 2 Diabetes | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Hypoglycemia & Weight After Treatment With GLP-1 RA + Basal Insulin | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide Hypoglycemia PPT | NDEI
AACE 2015 Diabetes Guidelines Glycemic Target A1C PPT | NDEI
AACE 2015 Diabetes Guidelines Lifestyle Changes Diet Exercise PPT | NDEI
AACE 2015 Diabetes Guidelines Hypoglycemia Management PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring in the Hospital In-Patient | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring CGM SMBG PPT | NDEI
ADA EASD Position Statement Individualized Glycemic Targets PPT | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
Hypoglycemia & CVD Risk Type 2 Diabetes AHA ACC Guidelines PPT | NDEI
Safety of Dulaglutide & Insulin Glargine Pancreatitis AWARD-2 | NDEI
Physical Activity in Patietns With Hypoglycemia ADA Diabetes Guidelines | NDEI
Managing Hypoglycemia in Diabetes ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
Glycemic Targets for Children With Type 1 Diabetes ADA Guidelines | NDEI
AWARD-2 Similar Adverse Events With Dulaglutide & Insulin Glargine Type 2 Diabetes | NDEI
Glycemic Control Guidelines to Prevent Diabetic Foot Ulcers A1C PPT | NDEI
LEADER Cardiovascular Safety of Liraglutide CVOT PPT | NDEI
Metabolic Surgery Postoperative Follow-Up for Type 2 Diabetes Guidelines | NDEI